At ASH's annual meeting, a study showed the potential for this method to inform the next treatment after patients relapse on BCMA- or GPRC5D-targeted therapy.

SAN DIEGO — It’s been decades since Vincent Rajkumar, a multiple myeloma physician and researcher at the Mayo Clinic, remembers first feeling that he was treating patients far too late.

Multiple myeloma and AL amyloidosis are conditions ... AL amyloidosis is more common in males than females. biopsy, to check for amyloid protein, which may take fat from the abdomen or tissue ...

In the study, a treatment combination including the drug, called Blenrep, cut the risk of death by 42% among patients with multiple myeloma, a result that was statistically significant and that He ...

So, with tissue testing, a lot of times we didn't have enough tissue to get things done, so liquid biopsy has made a huge difference. A lot of times when you don't have enough tissue or you can't ...

“We will find a cure in my reign as chairman of Myeloma Australia,” Browne said in an exclusive interview. “I will stay there until it happens.” “I’ve got skin in this game. I’ve ...

Plasma cell leukemia (PCL) is an aggressive and high-risk variant of multiple myeloma (MM) with a very poor prognosis. Given its rarity and aggressiveness, there is a lack of clinical trials testing ...

Patients with relapsed/refractory multiple myeloma (RRMM ... There were 26% of patients with extramedullary disease and 39% had high-risk cytogenetics. The number of prior lines of therapy ...